Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ALMS vs ZBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ZBIO Captures Overall Composite Edge (49.4 HOLD vs 43.3 HOLD), While ALMS Leads 3–2 on Growth & Valuation Pillars

ZBIO Overall Winner 6-Pillar Tally: ALMS 3 – 2 ZBIO (1 Tie) Matrix Metrics: ALMS 2 – 5 ZBIO

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.14 (N/M Forward P/E, -5938.1% operating margin) versus ZBIO at $27.93 (N/M Forward P/E, -2747.5% operating margin).

  • Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.16β · 59% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ALMS vs ZBIO
ALMS NASDAQ
Alumis Inc. Common Stock
Pharmaceutical Preparations
$5.14
-8.21% 1D
Market Cap $727.0M
TTM Revenue $7.2M
Forward P/E N/M
Beta / 30D Vol 2.24β · 86% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 20.0 Fund 51.0 Flow 67.0 Mom 74.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -45.8%), weak momentum, RSI 30
RSI-14: 29.8 · SMA20: $6.43 · SMA50: $7.12
ZBIO NASDAQ Head-to-Head Winner
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48

6-Pillar Scorecard Institutional Category Breakdown (ALMS 3 – 2 ZBIO)

Columns: Metric · ALMS · ZBIO
1. Valuation Multiples ALMS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 96.7x N/M
2. Growth & Scale ALMS
Revenue Growth (YoY) -7.7% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.2M $11M
Market Cap $727.0M $1.9B
3. Profitability & Quality ALMS
Gross Margin 100.0% N/A
Operating Margin -5938.1% -2747.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -110.9% -265.1%
4. Balance Sheet & Cash Flow ZBIO
Cash Generation (TTM) -$352M -$273M
Cash Flow Margin N/A N/A
Net Cash / Leverage $27M Net Cash $177M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 68.4% (6th %ile) 103.9% (13th %ile)
Put/Call OI Skew 4433.18x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ALMS (2) vs ZBIO (5)
Institutional Metric ALMS ZBIO Criterion Row Edge
Market Capitalization
Scale
$727.0M $1.9B Larger Scale ZBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-7.7% -100.0% Higher Growth ALMS
Operating Margin (TTM)
Profitability
-5938.1% -2747.5% Higher Margin ZBIO
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-110.9% -265.1% Higher ROE ALMS
52-Week Range Position
Momentum
2% ($5–$31) 46% ($14–$45) Stronger Trend ZBIO
Beta / 30D Volatility
Risk Regime
2.24β · 86% Vol 1.16β · 59% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$7.2M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 96.7x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$352M ($27M Net Cash) -$273M ($177M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZBIO +28.45 pp
ALMS: -16.01% · ZBIO: +12.44%
3M Horizon ZBIO +66.87 pp
ALMS: -79.34% · ZBIO: -12.47%
6M Horizon ZBIO +140.87 pp
ALMS: -75.7% · ZBIO: +65.17%
1Y Horizon ALMS +19.03 pp
ALMS: -2.65% · ZBIO: -21.68%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ALMS Revenue ZBIO Revenue ALMS Op. Margin ZBIO Op. Margin Margin Leader
FY2023 N/A $50M N/A -74.3% ZBIO
FY2024 N/A $10M N/A -3277.8% ZBIO
FY2025 $20M $10M -1886.9% -3830.6% ALMS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ALMS BREAKDOWN
91d in phase · OBV NEUTRAL
Current IV 68.4%
IV Percentile 6th %ile
Put/Call OI Skew 4433.18x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ALMS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ALMS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $727.0M market capitalization and -5938.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ALMS vs ZBIO Key Questions & Quantitative Answers

As of Nov 16, 2026, Zenas BioPharma, Inc. (ZBIO) captures the overall head-to-head institutional edge over Alumis Inc. (ALMS) on higher Unified Composite conviction (49.4/100 HOLD vs. 43.3/100 HOLD) after splitting the core matrix 5–2 (led by Balance Sheet & Cash Flow, Options & Positioning), while ALMS wins 3–2 across the 6-pillar growth and valuation breakdown. ALMS trades at $5.14 (N/M Forward P/E, -5938.1% operating margin) versus ZBIO at $27.93 (N/M Forward P/E, -2747.5% operating margin). Growth vs. Quality Trade-Off: ZBIO earns the overall head-to-head edge with a stronger Unified Composite Score (49.4/100 HOLD vs. ALMS 43.3/100 HOLD) and 1.16β · 59% Vol risk profile, whereas ALMS leads top-line expansion (-7.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ALMS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.8); meanwhile ZBIO is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ALMS leads the Growth & Scale pillar: ALMS posts -7.7% YoY revenue growth and +0.0% YoY earnings growth on $7.2M TTM revenue (100.0% gross margin, -5938.1% operating margin), compared with ZBIO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin). Across the 3-period historical trajectory (FY2023 to FY2025), ALMS cumulative revenue shifted N/A while ZBIO shifted -80.0%. In operating R&D and SG&A reinvestment, ALMS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ZBIO.

ALMS screens cheaper on headline valuation multiples. ALMS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 96.7x EV/Revenue (unreported FCF margin), whereas ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ALMS (-110.9% ROE) versus ZBIO (-265.1% ROE) capital efficiency.

In options market volatility and institutional positioning, ALMS carries 68.4% implied volatility (6th %ile, Compressed (<25th %ile)), a 4433.18x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk). By comparison, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.